Binimetinib is associated with patent WO2003077914A1 [1]. This patent application, filed on December 23, 2002, by Array BioPharma Inc., describes compounds that inhibit MEK kinases [1][2]. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway, which is frequently hyperactivated in various cancers [2].
What is Binimetinib used for?
Binimetinib is approved for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation [3]. It is often used in combination with encorafenib [3].
How does Binimetinib work?
Binimetinib is a potent and selective inhibitor of MEK1 and MEK2 enzymes [2]. By inhibiting MEK, binimetinib disrupts the RAS/RAF/MEK/ERK signaling pathway, thereby suppressing tumor cell proliferation and promoting apoptosis [2][4].
When does the patent for Binimetinib expire?
The original patent application WO2003077914A1 is a foundational document describing the compounds. However, patent exclusivity for a drug is determined by a portfolio of patents covering the compound, its manufacturing, and its uses. The specific patent expiry dates can be complex and may involve multiple patents. Information on patent expiry for drugs like binimetinib is available on resources such as DrugPatentWatch.com [5].
What are the risks associated with Binimetinib treatment?
Common side effects of binimetinib include fatigue, nausea, diarrhea, vomiting, abdominal pain, and muscle pain [3]. More serious risks can involve cardiac dysfunction, venous thromboembolism, ocular toxicity, and skin toxicities [3].
Who developed Binimetinib?
Binimetinib was developed by Array BioPharma Inc. [1]. It is marketed by Pfizer Inc. under the brand name Mektovi [3].
What are alternative treatments for BRAF-mutated melanoma?
Other treatments for BRAF-mutated melanoma include targeted therapies like dabrafenib and vemurafenib, which also target the BRAF pathway [6]. Immunotherapies, such as pembrolizumab and nivolumab, are also used, often as first-line treatment or in cases of resistance to targeted therapies [6].
What is the significance of MEK inhibition in cancer treatment?
MEK is a crucial signaling molecule in the MAPK pathway, which is critical for cell growth, proliferation, and survival. Dysregulation of this pathway is common in many cancers. Inhibiting MEK, as binimetinib does, can effectively block this aberrant signaling and slow or stop cancer progression [2][4].
Can biosimilars be developed for Binimetinib?
The development of biosimilars for small molecule drugs like binimetinib is not applicable in the same way as for biologics. However, generic versions of small molecule drugs can be developed and approved once the relevant patents expire and exclusivity periods have ended [5].
Sources:
[1] WO2003077914A1 - MEK INHIBITORS
[2] Array BioPharma Inc. (2002). MEK INHIBITORS. WO2003077914A1.
[3] Mektovi (binimetinib) prescribing information.
[4] L. W. Robert, et al. (2019). Binimetinib, a selective MEK inhibitor, in combination with Encorafenib, a BRAF inhibitor, for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations: Extended follow-up of a randomized phase III trial. Journal of Clinical Oncology, 37(19), 1671-1678.
[5] DrugPatentWatch.com
[6] National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Melanoma.